GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analysts give GoodRx an average rating of "Hold" across 15 research firms (3 sell / 7 hold / 5 buy) with a mean 12‑month price target of about $3.85, and several firms (including Goldman Sachs and Wall Street Zen) have recently cut ratings or price targets.
• GoodRx reported quarterly EPS of $0.09 (in line with estimates) and revenue of $194.8M, down 1.9% year‑over‑year, with analysts forecasting ~$0.13 EPS for the current fiscal year.
• The stock trades near $2.19 (52‑week range $1.77–$5.81) with a market cap around $750M, and institutional investors hold about 63.77% of shares, including a 517% stake increase by LSV Asset Management last quarter.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has earned an average rating of "Hold" from the fifteen research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $3.8542.

Several research analysts have weighed in on the company. Wall Street Zen downgraded GoodRx from a "buy" rating to a "hold" rating in a research note on Sunday, January 25th. The Goldman Sachs Group dropped their price target on GoodRx from $4.00 to $2.50 and set a "neutral" rating for the company in a research note on Monday, March 2nd. Leerink Partners restated an "outperform" rating and issued a $3.00 price target on shares of GoodRx in a research note on Thursday, February 26th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of GoodRx in a research note on Friday, February 27th. Finally, Morgan Stanley decreased their price target on shares of GoodRx from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Thursday, December 18th.

Institutional Trading of GoodRx

Hedge funds have recently bought and sold shares of the stock. LSV Asset Management increased its stake in GoodRx by 517.1% in the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company's stock worth $9,960,000 after acquiring an additional 1,973,017 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in GoodRx in the 3rd quarter worth approximately $3,036,000. Pacer Advisors Inc. bought a new stake in GoodRx in the 3rd quarter worth approximately $3,687,000. Pathway Capital Management LP increased its stake in GoodRx by 69.0% in the 3rd quarter. Pathway Capital Management LP now owns 986,158 shares of the company's stock worth $4,171,000 after acquiring an additional 402,721 shares during the last quarter. Finally, Versor Investments LP bought a new stake in GoodRx in the 3rd quarter worth approximately $155,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Trading Up 1.4%

Shares of GDRX stock opened at $2.19 on Friday. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market capitalization of $750.23 million, a PE ratio of 24.34, a PEG ratio of 1.49 and a beta of 1.47. The stock has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $2.83.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The business had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the prior year, the business posted $0.09 EPS. GoodRx's revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts predict that GoodRx will post 0.13 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.